Week In Review: Four China Biopharmas Announce $100+ Million Deals In First Week Of 2020
January 11, 2020 at 16:11 PM EST
Apollomics of Hangzhou announced a $189 million agreement to develop two GlycoMimetics novel E-selectin-based immunotherapies in China for leukemia. Apollomics will be responsible for developing uproleselan and GMI-1687.
